Morgan Stanley’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.42B | Buy |
3,188,881
+68,571
| +2% | +$32M | 0.09% | 209 |
|
|
2025
Q4 | $1.41B | Buy |
3,120,310
+11,905
| +0.4% | +$5.13M | 0.08% | 211 |
|
|
2025
Q3 | $1.22B | Sell |
3,108,405
-223,034
| -7% | -$93.2M | 0.07% | 235 |
|
|
2025
Q2 | $1.48B | Sell |
3,331,439
-77,081
| -2% | -$35.5M | 0.1% | 182 |
|
|
2025
Q1 | $1.65B | Buy |
3,408,520
+237,133
| +7% | +$111M | 0.12% | 154 |
|
|
2024
Q4 | $1.28B | Buy |
3,171,387
+132,950
| +4% | +$61.6M | 0.09% | 196 |
|
|
2024
Q3 | $1.41B | Sell |
3,038,437
-220,191
| -7% | -$106M | 0.1% | 178 |
|
|
2024
Q2 | $1.53B | Buy |
3,258,628
+74,162
| +2% | +$32.2M | 0.12% | 161 |
|
|
2024
Q1 | $1.33B | Sell |
3,184,466
-2,776,444
| -47% | -$1.17B | 0.11% | 181 |
|
|
2023
Q4 | $2.43B | Buy |
5,960,910
+3,090,809
| +108% | +$1.14B | 0.11% | 173 |
|
|
2023
Q3 | $998M | Buy |
2,870,101
+89,217
| +3% | +$31.2M | 0.1% | 189 |
|
|
2023
Q2 | $979M | Buy |
2,780,884
+427,823
| +18% | +$144M | 0.1% | 199 |
|
|
2023
Q1 | $741M | Sell |
2,353,061
-225,383
| -9% | -$67.6M | 0.08% | 246 |
|
|
2022
Q4 | $745M | Buy |
2,578,444
+640,899
| +33% | +$195M | 0.08% | 232 |
|
|
2022
Q3 | $561M | Buy |
1,937,545
+110,320
| +6% | +$31.7M | 0.08% | 245 |
|
|
2022
Q2 | $515M | Buy |
1,827,225
+1,001,376
| +121% | +$268M | 0.07% | 285 |
|
|
2022
Q1 | $216M | Sell |
825,849
-143,958
| -15% | -$34.2M | 0.03% | 504 |
|
|
2021
Q4 | $213M | Sell |
969,807
-72,706
| -7% | -$14.1M | 0.03% | 540 |
|
|
2021
Q3 | $189M | Sell |
1,042,513
-178,813
| -15% | -$34.9M | 0.03% | 550 |
|
|
2021
Q2 | $246M | Buy |
1,221,326
+325,944
| +36% | +$68.2M | 0.03% | 470 |
|
|
2021
Q1 | $192M | Sell |
895,382
-22,466
| -2% | -$4.93M | 0.03% | 499 |
|
|
2020
Q4 | $217M | Buy |
917,848
+144,325
| +19% | +$33.1M | 0.03% | 441 |
|
|
2020
Q3 | $210M | Buy |
773,523
+84,605
| +12% | +$23.3M | 0.04% | 372 |
|
|
2020
Q2 | $200M | Buy |
688,918
+13,423
| +2% | +$3.64M | 0.04% | 353 |
|
|
2020
Q1 | $161M | Sell |
675,495
-95,051
| -12% | -$21.8M | 0.04% | 360 |
|
|
2019
Q4 | $169M | Buy |
770,546
+204,727
| +36% | +$41.4M | 0.04% | 428 |
|
|
2019
Q3 | $95.9M | Buy |
565,819
+17,022
| +3% | +$3.01M | 0.03% | 576 |
|
|
2019
Q2 | $101M | Buy |
548,797
+37,505
| +7% | +$6.56M | 0.03% | 553 |
|
|
2019
Q1 | $94.1M | Sell |
511,292
-235,848
| -32% | -$43.6M | 0.03% | 559 |
|
|
2018
Q4 | $124M | Buy |
747,140
+56,373
| +8% | +$9.77M | 0.04% | 451 |
|
|
2018
Q3 | $133M | Buy |
690,767
+69,242
| +11% | +$12.3M | 0.03% | 496 |
|
|
2018
Q2 | $106M | Sell |
621,525
-171,161
| -22% | -$26.5M | 0.03% | 552 |
|
|
2018
Q1 | $129M | Sell |
792,686
-503,385
| -39% | -$82.2M | 0.04% | 473 |
|
|
2017
Q4 | $194M | Buy |
1,296,071
+461,814
| +55% | +$68.4M | 0.05% | 357 |
|
|
2017
Q3 | $127M | Sell |
834,257
-830,154
| -50% | -$125M | 0.04% | 458 |
|
|
2017
Q2 | $214M | Buy |
1,664,411
+1,060,009
| +175% | +$128M | 0.06% | 309 |
|
|
2017
Q1 | $66.1M | Buy |
604,402
+325,994
| +117% | +$28.7M | 0.02% | 760 |
|
|
2016
Q4 | $20.5M | Sell |
278,408
-447,413
| -62% | -$36.4M | 0.01% | 1505 |
|
|
2016
Q3 | $63.3M | Buy |
725,821
+529,262
| +269% | +$50M | 0.02% | 728 |
|
|
2016
Q2 | $16.9M | Sell |
196,559
-162,543
| -45% | -$14M | 0.01% | 1550 |
|
|
2016
Q1 | $28.5M | Buy |
359,102
+49,276
| +16% | +$4.46M | 0.01% | 1091 |
|
|
2015
Q4 | $39M | Buy |
309,826
+112,441
| +57% | +$13.6M | 0.01% | 932 |
|
|
2015
Q3 | $20.6M | Buy |
197,385
+733
| +0.4% | +$94.2K | 0.01% | 1342 |
|
|
2015
Q2 | $24.3M | Sell |
196,652
-16,436
| -8% | -$2.07M | 0.01% | 1331 |
|
|
2015
Q1 | $25.1M | Sell |
213,088
-70,998
| -25% | -$8.51M | 0.01% | 1279 |
|
|
2014
Q4 | $33.7M | Buy |
284,086
+26,947
| +10% | +$3.03M | 0.01% | 1087 |
|
|
2014
Q3 | $28.9M | Sell |
257,139
-133,800
| -34% | -$12.7M | 0.01% | 1160 |
|
|
2014
Q2 | $37M | Buy |
390,939
+204,758
| +110% | +$14.4M | 0.01% | 970 |
|
|
2014
Q1 | $13.2M | Sell |
186,181
-69,328
| -27% | -$5.49M | 0.01% | 1738 |
|
|
2013
Q4 | $19M | Sell |
255,509
-133,621
| -34% | -$9.31M | 0.01% | 1390 |
|
|
2013
Q3 | $29.5M | Buy |
389,130
+110,169
| +39% | +$8.77M | 0.01% | 962 |
|
|
2013
Q2 | $22.3M | Buy |
+278,961
| New | +$20.5M | 0.01% | 1105 |
|
Other funds holding VRTX
VCM
VPM
Morgan Stanley's VRTX Position: Q1 2026 in Review
Morgan Stanley increased its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, buying an estimated $32M and bringing the position to 3,188,881 shares worth $1.42B. The position accounts for 0.09% of the portfolio, ranked #209.
Morgan Stanley first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.43B in Q4 2023. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Morgan Stanley held 3,188,881 shares of Vertex Pharmaceuticals worth $1.42B as of Q1 2026.
- Morgan Stanley bought 68,571 Vertex Pharmaceuticals shares in Q1 2026, an estimated $32M.
- Vertex Pharmaceuticals made up 0.09% of Morgan Stanley's portfolio in Q1 2026, its #209 holding.
- Morgan Stanley first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Vertex Pharmaceuticals position peaked at $2.43B in Q4 2023.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.